This session aims to provide an overview of current bowel cancer research studies in prevention and early detection and discuss the potential of this area of research for one of the biggest cancer killers in the UK.
Speakers will present data from some current bowel cancer trials:
- COLO-COHORT, a study aimed at identifying factors that best predict patients at high risk of colorectal cancer.
- COLO-PREVENT, a platform for developing colorectal cancer prevention strategies.
- CONSCOP2, a randomised controlled trial of contrast-enhanced colonoscopy in the reduction of right-sided bowel cancer. Participants will also learn about the role of translational gastroenterology.
By the end of the session participants will have had the opportunity to learn about recent and new studies in this area, any scope for development, as well as appreciate the challenges to overcome and opportunities to seize for the benefit of patients.
- Professor Richard Adams – Cardiff University and Velindre Cancer Centre and Chair of the NCRI Colorectal Group, UK
- Dr Sunil Dolwani – Cardiff University, UK
- Dr Philip Dunne – Queen’s University Belfast and Deputy Chair of the NCRI Colorectal Group, UK
- Professor Simon Leedham – University of Oxford, UK
- Dr Suparna Mitra – University of Leeds, UK
- Professor Anne Thomas – University of Leicester, UK
1 category 1 (external) CPD credit for this session has been approved by the Federation of the Royal Colleges of Physicians. Delegates requiring a CPD certificate can add this during the registration process for a charge of £15. CPD Certificates will be sent automatically up to 10 days after the event date.
Who should attend?
Anyone interested or working in bowel cancer research, diagnosis or treatment. This includes patients and carers formally involved in research, scientists, medical/clinical oncologists, GPs, surgeons, early career researchers, nurses, allied health professionals, gastroenterologists, PhD and undergraduate students, research teams and research managers/funders.